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Abstract
Background: The previously published “Dose Response Multicentre International Collaborative Initiative (DoReMi)”
study concluded that the high mortality of critically ill patients with acute kidney injury (AKI) was unlikely to be related
to an inadequate dose of renal replacement therapy (RRT) and other factors were contributing. This follow-up study
aimed to investigate the impact of daily fluid balance and fluid accumulation on mortality of critically ill patients
without AKI (N-AKI), with AKI (AKI) and with AKI on RRT (AKI-RRT) receiving an adequate dose of RRT.
Methods: We prospectively enrolled all consecutive patients admitted to 21 intensive care units (ICUs) from nine
countries and collected baseline characteristics, comorbidities, severity of illness, presence of sepsis, daily physiologic
parameters and fluid intake-output, AKI stage, need for RRT and survival status. Daily fluid balance was computed and
fluid overload (FO) was defined as percentage of admission body weight (BW). Maximum fluid overload (MFO) was the
peak value of FO.
Results: We analysed 1734 patients. A total of 991 (57 %) had N-AKI, 560 (32 %) had AKI but did not have RRT and 183
(11 %) had AKI-RRT. ICU mortality was 22.3 % in AKI patients and 5.6 % in those without AKI (p < 0.0001). Progressive
fluid accumulation was seen in all three groups. Maximum fluid accumulation occurred on day 2 in N-AKI patients
(2.8 % of BW), on day 3 in AKI patients not receiving RRT (4.3 % of BW) and on day 5 in AKI-RRT patients (7.9 % of BW).
The main findings were: (1) the odds ratio (OR) for hospital mortality increased by 1.075 (95 % confidence interval 1.
055–1.095) with every 1 % increase of MFO. When adjusting for severity of illness and AKI status, the OR changed to 1.
044. This phenomenon was a continuum and independent of thresholds as previously reported. (2) Multivariate
analysis confirmed that the speed of fluid accumulation was independently associated with ICU mortality. (3) Fluid
accumulation increased significantly in the 3-day period prior to the diagnosis of AKI and peaked 3 days later.
Conclusions: In critically ill patients, the severity and speed of fluid accumulation are independent risk factors for ICU
mortality. Fluid balance abnormality precedes and follows the diagnosis of AKI.
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Background
Renal replacement therapy (RRT) constitutes a key com-
ponent of modern critical care, together with mechanical
ventilation, fluid resuscitation and vasopressor support.
The main reasons for initiation are acute kidney injury
(AKI) and fluid overload (FO). There is growing evidence
that FO is harmful and associated with a longer hospital
stay and increased morbidity and mortality [1–3]. FO may
be present at admission or develop during ICU stay due to
a combination of oliguria and liberal fluid administration
leading to a positive fluid balance [4, 5].
FO accounts for an increased risk of death in patients
with AKI [6, 7]. Furthermore, fluid accumulation itself
may be independently associated with an increased risk
of developing AKI and mortality. In a secondary analysis
of the SOAP study, Payen et al. showed that the average
daily fluid balance in the first 7 days was significantly
more positive in patients with AKI [1]. Bouchard et al.
demonstrated that crude mortality was higher in AKI pa-
tients when fluid overload was present [8]. Subsequent
studies confirmed that both, severity of FO and the number
of days spent with FO, were risk factors for poor outcome.
We previously published a prospective cohort observa-
tional study, the “Dose Response Multicentre Inter-
national Collaborative Initiative (DoReMi)” [9], which
evaluated the practice of continuous renal replacement
therapy (CRRT) in patients in the intensive care unit
(ICU). The study confirmed that in spite of a discrepancy
(−25 %) between effective (27 ml/kg/h) and prescribed
(34 ml/kg/h) dose, the median delivered dose was
considered adequate based on two recent large trials
(RCTs) [10, 11]. The DoReMi study therefore concluded
that the high mortality observed in AKI patients was not
related to inadequate treatment dose but to other possible
factors instead.
The “Dose Response Multicentre Investigation on
Fluid Assessment (DoReMIFA)” study is an evolution of
the previous DoReMi study. It aimed to prospectively
evaluate the practice of fluid management in the ICU,
including patients with AKI (AKI) and without AKI
(N-AKI), and patients with AKI treated with RRT
(AKI-RRT) in different ICUs (in Europe, the Far East and
Latin America). The main objective of this study was to
investigate whether fluid balance throughout ICU stay and
during RRT affects mortality of ICU patients. Data collec-
tion and analysis was facilitated by the use of electronic
medical records and web-based case report forms (CRFs).
Methods
The study protocol was made available for review to
ICU physicians from different countries. Once the ICU
was enrolled in the research group, data were collected
for all admitted patients for 3 consecutive months, in
the period between April 2012 and September 2014
using an electronic case report form. Exclusion criteria
were (a) age <18 years or >85 years; (b) chronic dialysis;
(c) short-term postoperative admission; (d) life expect-
ancy less than 48 h; (e) need for extracorporeal mem-
brane oxygenation (ECMO) within the first 48 h of ICU
stay. All types of ICUs were eligible on voluntary basis
within the indicated period. Local ethics committees ap-
proved the study according to the local regulations.
Data collection
We designed a specific password-protected website for
the study. Centres could only access data related to their
patients. An automatic data verification system screened
each field for missing or out-of-range values and data in-
consistencies, generating a visual alert. The online tool
included seven sections: (1) Demographics, anthropo-
metrics, and admission diagnoses; (2) Medical history;
(3) Admission data; (4) Daily vital signs and laboratory
values; (5) RRT; (6) Sepsis and (7) Outcomes/case clos-
ure. Data input was on daily basis. Severity of illness was
defined by Simplified Acute Physiology Score II (SAPS
II) [12], Sequential Organ Failure Assessment (SOFA)
[13] and Acute Physiology and Chronic Health Evalu-
ation II (APACHE II) [14] scores at admission and de-
scribed in a pie chart (Additional file 1: Figure S1). AKI
diagnosis was based on creatinine (Cr) levels using the
KDIGO classification [15]. The creatinine value prior to
hospitalization (Medical history) was used as baseline. If
missing, a reference creatinine was requested utilizing
the Modification of Diet in Renal Disease (MDRD) for-
mula assuming a glomerular filtration rate of 75 ml/
min/1.73 m2. Daily data entry included serum creatinine,
total fluid intake and output, urine volume, ventilation
modality, diuretic therapy and, if present, RRT. As soon
as a patient met the criteria for AKI, a full data entry
section was activated for 14 days with automatic daily
display of AKI stage. Data for SOFA calculation and for
epinephrine/norepinephrine dose were additionally in-
cluded. A dynamic chart displaying fluid balance and
clinical management was generated using the data en-
tered daily (see Additional file 1: Figure S2). The RRT
section included data on modality, flows (blood, dialys-
ate, reinfusion, pre/post ratio, and net ultrafiltration
rate), anticoagulation, duration (for each 24-h period),
reason for initiation, type of vascular access and malfunc-
tions. RRT fields were automatically adjusted according to
treatment modality. It was mandatory to report the cause
of downtime whenever the effective treatment time was
less than that prescribed. Data on circuit life span were
recorded for each treatment. The case closure section
included data on outcome and renal status at discharge.
Data on fluid balance were automatically calculated by
the CRF from the time of admission, based on daily
data entry.
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Table 1 Demographics and baseline data
Patient characteristics All patients
(n = 1734)
Patients without AKI
(n = 991) 57.2 %
Patients with AKIb
(n = 743) 42.8 %
p value
Male gender (%) 65.34 % 64.08 % 67.03 % 0.2016
Age in years, mean ± SD 59.23 ± 15.19 57.56 ± 15.48 61.46 ± 14.50 <0.0001
Weight in kg, mean ± SD 75.16 ± 16.89 73.49 ± 15.69 77.38 ± 18.15 <0.0001
- % measured weight 67.99 % 66.20 % 70.39 % 0.0639
Creatinine reference in mg/dl, mean ± SD 1.13 ± 1.02 1.00 ± 0.68 1.29 ± 1.33 <0.0001
- % measured Cr 63.78 % 61.96 % 66.22 %
Creatinine at baseline in mg/dl 1.14 ± 1.02 1.01 ± 0.78 1.31 ± 1.26 <0.0001
Reason for admission (%) <0.0001
- Cardiovascular 37.60 36.43 39.17
- Respiratory 11.53 10.60 12.79
- Gastrointestinal 9.46 8.27 11.04
- Trauma 10.32 13.42 6.19
- Transplant 1.44 0.81 2.29
- Infections 7.73 5.15 11.17
- Neurologic 12.92 17.56 6.73
- Other 8.82 7.77 10.23
Severity of illness scores (mean ± SD)
- SAPS II 39.12 ± 16.99 35.04 ± 15.39 44.56 ± 17.50 <0.0001
- APACHE II 17.11 ± 7.66 15.14 ± 6.74 19.74 ± 8.03 <0.0001
- SOFA 6.63 ± 3.66 5.49 ± 3.16 8.15 ± 3.74 <0.0001
Renal pathologies (%)
- Proteinuria/hematuria 0.98 0.20 2.02 <0.0001
- CKD not on dialysis 8.07 4.94 12.25
- no CKD 65.22 69.83 59.08
- renal transplant 1.15 0.40 2.15
- no data available 24.57 24.62 24.50
Comorbidities (%)
- diabetes 21.40 17.05 27.19 <0.0001
- cardiovascular 45.79 43.29 49.13 0.0208
- hypertension 46.94 43.19 51.95 0.0004
Use of NSAIDs (%) 5.59 5.05 6.33 0.2510
Use of ACE-I/ARB (%) 13.09 13.52 12.52 0.5393
Mechanical ventilation (%)
- on admission 69.61 67.00 73.08 0.0125
- during ICU stay 83.45 79.31 88.96 <.0001
Respiratory support on admission (%) 0.0038
- none 20.88 22.81 18.30
- non-invasive ventilation 9.63 10.60 8.34
- invasive ventilation 59.98 56.41 64.74
Days on mechanical ventilation
- mean ± SD 6.35 ± 9.18 4.45 ± 6.53 8.87 ± 11.35 <0.0001
- median [IQR] 3.0 [1.0;8.0] 2.0 [1.0; 5.0] 5.0 [2.0; 13.0]
Sepsisa (%)
- on admission 23.35 17.25 31.36 <0.0001
- on first AKI day (or admission) 23.24 17.25 31.22 <0.0001
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Table 1 Demographics and baseline data (Continued)
- during ICU stay 34.14 25.43 45.76 <0.0001
Severity of sepsis on admission (%)
- SIRS 13.01 11.20 15.34 <0.0001
- sepsis 7.11 7.16 7.00
- severe sepsis 5.72 4.14 7.81
- septic shock 10.52 5.95 16.55
RRT in ICU (%) 11.42 % 1.51 % 24.63 % <0.0001
Death in ICU (%) 12.75 % 5.55 % 22.34 % <0.0001
Length of ICU stay (days)
- mean ± SD 9.54 ± 10.19 7.64 ± 7.71 12.07 ± 12.32 <0.0001
- median [IQR] 6.0 [3.0; 12.0] 5.0 [3.0; 9.0] 8.0 [4.0; 15.0]
Renal status at ICU discharge (%)
- Dialysis dependent 7.15 1.11 15.21 <0.0001
- Dialysis independent but renal function not returned to baseline 16.96 4.14 34.05
- renal function returned to baseline 7.67 4.04 12.52
- normal renal function 68.22 90.72 38.22
Measured weight: patient’s weight as measured on ICU admission (not estimated). Measured Cr: creatinine from laboratory and not estimated with MDRD
Abbreviations: AKI acute kidney injury, SD standard deviation, Cr creatinine, SAPS II Simplified Acute Physiology Score II, APACHE II Acute Physiology and Chronic
Health Evaluation II, SOFA Sequential Organ Failure Assessment, CKD chronic kidney disease, NSAID non-steroidal anti-inflammatory drug, ACE-I ACE inhibitor, ARB
angiotensin receptor blocker, ICU intensive care unit, IQR interquartile range, SIRS Systemic Inflammatory Response Syndrome, RRT renal replacement therapy
aSepsis includes: sepsis, severe sepsis, and septic shock
bAll AKI patients (AKI-RRT included)
Fig. 1 Patient flow chart. AKI acute kidney injury, Cr creatinine, RRT renal replacement therapy
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Definitions
Fluid overload (FO) was defined as the ratio between cu-
mulative fluid balance and the initial body weight, in
percentage. Maximum fluid overload (MFO) referred to
the peak value of FO observed during the entire ICU
stay. TMFO represented the number of days between
ICU admission and day of MFO. Fluid overload slope
(FOSL) was computed as the ratio MFO/TMFO and rep-
resented the velocity of fluid accumulation. The term
“AKI-RRT” defined AKI patients who received at least
one session of RRT while “AKI” referred to AKI patients
without RRT, when not differently specified. N-AKI de-
fined patients who never developed AKI. AKI stages
were based on the creatinine criteria of the KDIGO
classification.
Statistical analysis
Continuous variables were described as mean ± standard
deviation (SD) or median and interquartile range (IQR).
Percentages were calculated for categorical variables. Bi-
variate comparisons of patients with AKI and patients
without AKI were performed using the Wilcoxon rank-
sum test and the chi-square test, as appropriate.
Boxplots were used to illustrate the FO of the different
AKI groups (N-AKI, AKI and AKI-RRT) during the first
5 days of ICU stay. The Kruskal-Wallis test was per-
formed to explore whether the three groups differed on
individual days. The resulting p values were corrected
for the multiple test situations with the Bonferroni for-
mula. Post hoc tests, always comparing two groups, were
done using the Wilcoxon rank-sum test and p values
were corrected (Bonferroni).
To visualize the trend of fluid accumulation in refer-
ence to the development of AKI, the delta between FO
at AKI diagnosis and the FO at each day between 3 days
before and up to 3 days after diagnosis of AKI was cal-
culated. Patients were censored at the day of AKI recov-
ery. Means ± standard error (StdErr) of FO were plotted
for the whole 7-day period.
A figure with boxplots for the three groups (N-AKI,
AKI and AKI-RRT) illustrated the MFO during the ICU
stay. Similarly, for the AKI-RRT group, a boxplot de-
scribed the fluid status at different time points. Survivors
and non-survivors were also plotted. The horizontal axis
described the median day for the corresponding boxplot
event.
Fig. 2 Fluid accumulation for N-AKI, AKI, AKI-RRT patients during the first 5 days following admission. Looking at the first 5 days of ICU stay, the
cumulative fluids differed significantly each day among the three groups (N-AKI, AKI and AKI-RRT). (p and p* refer to the p values of the Kruskal-Wallis
test and the correction for the multiple test situation with the Bonferroni test, respectively). There was progressive fluid accumulation in N-AKI and
AKI patients. AKI-RRT patients accumulated a similar degree of fluid, followed by a decrease. Patients were daily assigned to the corresponding group
(N-AKI, AKI and AKI-RRT). AKI patients with acute kidney injury, AKI-RRT patients with acute kidney injury treated with renal replacement therapy, FO fluid
overload, N-AKI patients without AKI
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To characterize the FO prior to death or ICU dis-
charge, means ± StdErr of all patients who stayed in the
ICU for at least 5 days were plotted.
A Kaplan-Meier analysis was performed to predict the
time to death for the three AKI groups (N-AKI, AKI and
AKI-RRT) separately. The difference between the three
groups was tested by a log-rank test. This analysis was
restricted to the first 30 days of follow-up; patients who
stayed in the ICU for more than 30 days were censored
at this time.
An unadjusted logistic regression model was used to
illustrate the predicted probabilities of MFO on ICU
Fig. 4 Maximum FO (MFO) during ICU stay in N-AKI, AKI and AKI-RRT patients. MFO was higher in patients with AKI and particularly high in those
treated with RRT. The horizontal axis shows the median day when MFO occurred. AKI patients with acute kidney injury, AKI-RRT patients with
acute kidney injury treated with renal replacement therapy, N-AKI patients without AKI
Fig. 3 Delta of cumulative fluids pre and post day of AKI. The day of AKI served as a reference point. A backward calculation of cumulative fluid
balance was conducted for the 3-day period pre and post day of AKI. Patients were censored on day of AKI recovery. Fluid accumulation up to
3 % occurred within a few days. AKI acute kidney injury, FO fluid overload, StdErr standard error
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mortality. For this model, follow-up was restricted to the
median time in the ICU (12 days).
Additionally, the previous model was adjusted for
AKI status (yes/no during the first 12 days of follow-
up) and APACHE II score (at baseline). The predicted
probabilities for ICU death were plotted for different
APACHE II scores. For both models, the odds ratios
(OR) and corresponding 95 % confidence intervals
(CI) were reported.
Cox proportional hazard regression analysis was ap-
plied to evaluate the time to death. The main predictor
was FOSL. Hazard ratios (HR) and corresponding 95 %
confidence intervals were reported using an unadjusted
model as well as a model adjusted for: age, sex, SAPS II,
sepsis (yes/no, at admission), mechanical ventilation
(yes/no, at admission), diabetes (yes/no, at admission),
cardiovascular disease (yes/no, at admission), and hyper-
tension (yes/no, at admission). Only significant variables
were shown in the selected models.
P values less than 0.05 were considered to be signifi-
cant. The analysis was conducted with the statistical
software SAS, version 9.4 (SAS Institute Inc., Cary, NC,
USA).
Results
A total of 1734 patients from 21 ICUs of nine countries
were included in the study. The mean age was 59.2 ±
15.2 years, and 65.3 % were male. The main clinical rea-
sons for admission to ICU were severe cardiovascular
(37.6 %), neurologic (12.9 %) and respiratory (11.5 %)
problems. A total of 64 % of patients were admitted to
the ICU within 24 hours from hospital admission. The
mean SAPS II, APACHE II and SOFA scores on admis-
sion to the ICU were 39.12 ± 16.99, 17.11 ± 7.66 and
6.63 ± 3.66, respectively. Mean length of stay was 9.5 ±
10.2 days (range 2–11 days) (Table 1).
Three hundred and thirteen patients (18 %) had AKI
on admission, 430 (25 %) developed AKI during their
ICU stay and 183 (25 % of patients with AKI) received
RRT (Fig. 1). Among patients with AKI, 66 % had stage
I, 18 % stage II and 16 % had stage III.
Patients with AKI (AKI-RRT included) were older, had
a higher reference and baseline serum creatinine level,
were more often diabetic and septic (both at admission
and during the ICU course) and spent more days on
mechanical ventilation. Their crude mortality was higher
after a longer stay in the ICU (Table 1).
Fig. 5 Cumulative fluid balance of AKI patients treated with renal replacement therapy. The cumulative fluid balance of AKI-RRT patients is illustrated
at four different time points: (a) day of AKI diagnosis, (b) day of RRT, (c) day of maximum FO (MFO), (d) last RRT day. Cumulative fluid balances were
computed also for survivors and non-survivors. The horizontal axis shows the median day when the relevant events occurred. AKI acute kidney injury,
AKI-RRT patients with acute kidney injury treated with renal replacement therapy, IQR interquartile range
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Fluid accumulation and time course
There was a progressive fluid accumulation in N-AKI
and AKI patients at different time points from admis-
sion. AKI-RRT patients had a following decrease
(Fig. 2). The three groups showed significantly differ-
ent degrees of FO at all time points. The differences
remained significant after adjusting for the multiple
test situation (Bonferroni). (Post hoc test in Additional
file 2: Table S1).
In AKI patients, fluid accumulation began 3 days prior
to AKI diagnosis and continued afterwards, resulting in
a total fluid accumulation of 3 % 3 days after develop-
ment of AKI (Fig. 3).
Maximum fluid overload (MFO) was of 2.8 % of body
weight (IQR 0.8–5.6) (on day 2) in N-AKI and 4.3 %
(IQR 1.5–9) (on day 3) in AKI (Fig. 4). In AKI-RRT pa-
tients, MFO was 7.9 % (IQR 3.1–14.8) (on day 5). In this
group, FO was 2.5 % at AKI diagnosis, 3.3 % (IQR 0.6–
7.7) at initiation of RRT, and 7.9 % (IQR 3–10) on day 5.
On the day when RRT was discontinued (mean day 9),
FO was reduced to 2.7 % (IQR 0.6–7.7 %) (Fig. 5).
Fluid accumulation, mortality and time course
The Kaplan-Meier analysis including the first 30 days of
ICU stay indicated a significant survival benefit for pa-
tients without AKI (p < 0.0001). The AKI-RRT group
showed the lowest survival rate (Fig. 6). AKI patients
had intermediate chances of survival.
In the total population, non-survivors had significant
fluid accumulation in the 4 days prior to death (Fig. 7
and Additional file 2: Table S3). MFO was different be-
tween survivors and non-survivors (Fig. 8).
A logistic regression showed that MFO was a signifi-
cant risk factor for mortality. Every 1 % increase of MFO
was associated with an OR 1.075 for mortality (CI
1.055–1.095) (Table 2, unadjusted model). There was an
exponential relationship between fluid accumulation and
predicted probability of death in all patients (Fig. 9).
When adjusting the model for APACHE II and AKI sta-
tus during ICU stay (AKI Y/N), the OR decreased to
1.044 (CI 1.023–1.065) (Table 2, adjusted model). The
risk of death related to FO increased with severity of ill-
ness as defined by APACHE II score. AKI patients
(AKI-RRT included) had a significantly higher risk than
patients without AKI (Fig. 10).
Multivariable analyses
Cox regression analysis of the velocity of fluid accumula-
tion demonstrated that for every increase of one unit of
the FOSL, the hazard of death increased significantly by a
factor of 1.32 (Table 3). The hazard ratio decreased to 1.28
when adjusting for SAPS II score, sepsis on admission,
diabetes, cardiovascular disease and hypertension (Table 3,
Fig. 11).
Similar results were seen after patients were stratified
according to N-AKI, AKI, and AKI-RRT status. When
Fig. 6 Thirty-day survival of N-AKI, AKI, and AKI-RRT patients. The Kaplan-Meier analysis including the first 30 days of ICU stay indicated a
significant survival benefit for patients without AKI (p < 0.0001). The AKI-RRT group had the lowest survival rate and AKI patients who did
not receive RRT had intermediate survival rates. AKI patients with acute kidney injury, AKI-RRT patients with acute kidney injury treated with renal
replacement therapy, N-AKI patients without AKI
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Fig. 8 Maximum fluid overload in survivors and non-survivors. Maximum fluid overload (MFO) was calculated for survivors and non-survivors
among N-AKI, AKI and AKI-RRT patients. In all cohorts, non-survivors had a higher MFO. AKI patients with acute kidney injury, AKI-RRT patients with
acute kidney injury treated with renal replacement therapy, N-AKI patients without AKI
Fig. 7 Cumulative fluid balance prior to death or discharge. This analysis includes patients who stayed in the ICU for at least 5 days. Non-survivors
(n = 156) had progressive fluid accumulation in the 4 days before death whereas cumulative fluid balance decreased in survivors (n = 854). FO fluid
overload, StdErr standard error
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adjusting for risk factors, the hazard of death was no
longer significant for the N-AKI cohort (p = 0.0752)
(Table 4).
Daily fluid accumulation was a predictor of mortality
in the total population and in AKI patients. After adjust-
ment, daily fluid accumulation was not independently
associated with a higher risk of death in the N-AKI co-
hort, even in the context of a higher mean cumulative
fluid balance (Additional file 2: Table S2).
Discussion
Fluid therapy is an integral component of the manage-
ment of critically ill patients. However, wide variation in
clinical practice has been observed, in particular related
to type of fluid, rate of administration and methods for
assessing fluid responsiveness [16]. Our study shows that
ICU patients tended to accumulate fluid in various
degrees from the day of admission onwards. In AKI pa-
tients, more fluid accumulated between the 3 days prior
to the diagnosis of AKI and 3 days later. Despite the fact
that all groups accumulated fluid during the ICU stay,
AKI-RRT patients showed the highest degree of FO. In
this group, FO peaked several days after RRT initiation,
which indicates the challenges of removing fluid even
with extracorporeal support.
Our results are complementary to the findings of other
studies in the literature [17], but also provide new in-
sights into a very complex clinical problem.
Among the overall population as well as the subgroups
(N-AKI, AKI and AKI-RRT), non-survivors accumulated
more fluid. Moreover, there was a progressive increase
in fluid accumulation during the 4 days prior to death.
Patients without AKI had a survival benefit (univariate
model). The AKI-RRT group had the lowest survival rate
during the whole period while AKI patients had an inter-
mediate chance of survival, as previously described in
the literature [1, 3, 4, 8].
Furthermore, MFO was an independent risk factor for
mortality [OR 1.044 (CI 1.023–1.065)], and the predicted
probability of death increased exponentially. AKI patients,
including those receiving RRT, were more likely to die
than N-AKI. Moreover, the higher the MFO, the wider the
difference in mortality between the AKI and N-AKI co-
hort, which suggests that FO aggravates the patients’
underlying condition [18, 19]. This finding is novel and
Fig. 9 Impact of maximum fluid overload. The risk of death increased exponentially with the magnitude of maximum fluid overload (MFO). In
this model, follow-up was limited to the median time in ICU (12 days). Circles represent the number of observations of survivors and non-survivors
(at the bottom and at the top respectively)
Table 2 Logistic regression analysis to evaluate the effect of
fluid overload on ICU mortality
Unadjusted model Adjusted model
OR (95 % CI) OR (95 % CI)
MFO 1.075 (1.055–1.095) MFO 1.044 (1.023–1.065)
APACHE II 1.077 (1.054–1.101)
AKI (Yes vs No) 2.247 (1.532–3.295)
Abbreviations: OR odds ratio, CI confidence interval, MFO peak fluid overload,
APACHE II Acute Physiology and Chronic Health Evaluation II, AKI Yes: patients
met criteria for AKI
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has not been reported in the literature before. At variance,
the PICARD group and others [8, 20–22] concluded that
the risk of mortality was proportional to fluid accumula-
tion above a particular cutoff value. Our model predicted
the probability of death as a continuum, with an exponen-
tial relation to the MFO increase. This suggests that “fluid
overload” should be defined as any degree of positive fluid
balance rather than a value above an arbitrary cutoff.
We also demonstrated another difference between
N-AKI and AKI patients. It seemed that, while AKI
independently worsened patients’ outcome, the level of
maximum fluid overload was more harmful for patients
with AKI than the N-AKI cohort. In addition, severity of
illness as defined by APACHE II score was independently
associated with mortality. Of interest, the difference in
mortality risk between the AKI versus N-AKI cohort
tended to increase with higher APACHE II scores.
Our data showed that the velocity of fluid accumula-
tion is also important. Speculating on a possible role of
the fluid accumulation velocity, the more rapidly FO oc-
curred, the higher the risk of dying. For any one unit rise
of FOSL, the probability of death increased 27 times.
This finding was significant for all three subgroups in a
univariate analysis and remained significant for the AKI
cohort but not N-AKI patients after adjustment for
other risk factors. This observation may suggest that pa-
tients without AKI tolerate a positive fluid balance better
during the resuscitation and maintenance phase [23], es-
pecially those suffering from sepsis [24, 25].
Based on these results, it appears that, instead of using
an absolute fluid accumulation or FO value as a predictor
of poor patient outcome, fluid accumulation velocity may
have a more physiological rationale and a better statistical
power to serve as a tool for fluid assessment.
Conclusions
In conclusion, this is one of the largest prospective ob-
servational studies with data reflecting the real world of
clinical practice in the ICU. It is noteworthy that the
Table 3 Multivariable analysis of factors associated with
mortality
Unadjusted model Adjusted modela
HR (95 % CI) p HR (95 % CI) p
FOSL 1.32 (1.22–1.43) <0.001 1.28 (1.18–1.40) <0.0001
SAPS II 1.02 1.01–1.03 <0.0001
Sepsis 2.01 (1.52–2.65) <0.0001




Hypertension 0.67 (0.49–0.92) 0.012
Sepsis was evaluated on admission and included sepsis, severe sepsis and
septic shock. Diabetes, cardiovascular disease and hypertension were
comorbidities as recorded on admission. Use of diuretics (Y/N) at ICU
admission was not statistically significant and intentionally excluded in order
to avoid the risk of oversimplification
Abbreviations: HR hazard ratio, CI confidence interval, FOSL slope of fluid
accumulation, SAPS II Simplified Acute Physiology Score II
aOnly significant variables are shown
Fig. 10 Predicted probability of death adjusted for severity of illness. The figure shows maximum FO (MFO) and predicted probability of death
adjusted for APACHE II scores 1, 17.12, 27 and 53. For this model, follow-up was limited to the median time in ICU (12 days). AKI acute kidney
injury, APACHE II Acute Physiology and Chronic Health Evaluation II
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degree of FO observed in all patients independent of the
subgroups was quite low compared to previous studies,
which implies that a more careful fluid administration
policy has been implemented in most units. Neverthe-
less, although in most patients FO did not reach the
threshold of 5 % and only a small proportion of patients
exceeded an FO value of 10 %, risk of mortality was
dependent on fluid accumulation in a continuum. Our
study also confirms that daily fluid balance tends to be
positive in the majority of patients from the day of ad-
mission until discharge.
Our study shows that there is an increased risk of
dying at any level of FO, and rapidity of fluid
accumulation is particularly relevant. Despite these
novel findings, it is important to acknowledge some
limitations of the study. We recognise the lack of an
objective assessment of fluid status at admission and
appreciate that the impact of FO and MFO may have
been worse in patients who were already fluid over-
loaded on admission to the ICU. However, independ-
ent of fluid status on admission, fluid accumulation
occurred inexorably in almost all patients. These find-
ings should trigger further studies, in particular to
identify prospective measures to prevent the harmful
effects of fluid accumulation, especially if it occurs
rapidly.
Table 4 Multivariable Cox regression analysis of the impact of fluid accumulation on mortality risk in different subgroups
(N-AKI, AKI and AKI-RRT)
N-AKI AKIa AKI-RRT
HR (95 % CI) p HR (95 % CI) p HR (95 % CI) p
Unadjusted model
FOSL 1.28 (1.05–1.55) 0.0131 1.26 (1.11–1.44) 0.0005 1.20 (1.05–1.37) 0.0095
Adjusted (selected) modelb
FOSL 1.21 (0.98–1.49) 0.0752 1.31 (1.14–1.50) 0.0001 1.21 (1.04–1.42) 0.0137
Abbreviations: N-AKI patients without AKI, AKI patients with acute kidney injury, AKI-RRT patients with acute kidney injury treated with renal replacement therapy,
HR hazard ratio, CI confidence interval, FOSL slope of fluid accumulation
aAKI without RRT
bAdjusted for the same variables as listed in Table 3
Fig. 11 The speed of fluid accumulation. The fluid overload slope (FOSL) computed for three generic patients. Solid line: FO (%); dashed line: ICU
admission (FO = 0 %) to maximum FO (MFO) straight line; solid bold line: FO slope
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Additional files
Additional file 1: Figure S1. Scores displayed as a pie chart. Figure S2.
Fluid balance chart. The red dot represents the diuretics while the area
under the curve is the cumulative fluid. The green and blue lines are
respectively the total intake and the urine output. (DOCX 250 kb)
Additional file 2: Table S1. Post hoc test comparison. Table S2. On
multivariate Cox regression, the daily cumulative fluid was a predictor of
mortality for only the Overall population and AKI patients. After adjusted
analysis N-AKI patients were not independently associated with a higher risk
of death, even with a higher mean cumulative fluid overload. Table S3. FO
(%) on ICU discharge for Alive and Death patients. FO (%) for All patients, N-
AKI, AKI and AKI-RRT for
survivors and non-survivors. (DOCX 19 kb)
Abbreviations
ACE-I, ACE inhibitor; AKI, acute kidney injury; AKI-RRT, patients with AKI
treated with RRT; APACHE, Acute Physiology and Chronic Health Evaluation;
ARB, angiotensin receptor blocker; BW, body weight; CI, confidence interval;
CKD, chronic kidney disease; Cr, creatinine; CRFs, case report forms; CRRT,
continuous renal replacement therapy; DoReMi, The Dose Response Multi-
centre International Collaborative Initiative; ECMO, extracorporeal membrane
oxygenation; FO, fluid overload; FOSL, slope of fluid accumulation, HR, hazard
ratio; ICU, intensive care unit; IQR, interquartile range; MDRD, Modification of
Diet in Renal Disease; MFO, maximum fluid overload; MFO/TMFO, velocity of
fluid accumulation; N-AKI, patients without AKI; NSAID, non-steroidal anti-
inflammatory drug; OR, odds ratios; RRT, renal replacement therapy; SAPS,
Simplified Acute Physiology Score; SD, standard deviation; SOFA, Sequential
Organ Failure Assessment; StdErr, standard error; TMFO, number of days
between ICU admission and day of MFO
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